Results 251 to 260 of about 371,889 (314)

Stability and adaptability assessment of red onion genotypes using AMMI, GGE, BLUP, and multivariate indices. [PDF]

open access: yesFront Plant Sci
Gupta AJ   +6 more
europepmc   +1 more source

Maule's bulbs, roots and seeds : autumn 1927

open access: gold, 1927
Wm. Henry Maule (Firm)   +1 more
openalex   +2 more sources

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

open access: yesBMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen   +7 more
wiley   +1 more source

1929 annual : only the best seeds, bulbs and plants /

open access: gold, 1929
Aug. W. Masser   +2 more
openalex   +2 more sources

Does Accounting Scope 3 Emissions Improve Sustainable Business Outcomes? Evidence From the S&P 500 Technology Companies

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Corporate sustainability efforts increasingly emphasize Scope 3 emissions due to their substantial share of total corporate carbon footprints. However, reporting these emissions remains inconsistent, limiting transparency and comparability across firms.
Nuri C. Onat   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy